A fundamental task of pharmacogenetics is to collect and classify relationships between genes and drugs. Currently, this useful information has not been comprehensively aggregated in any database and remains scattered throughout the published literature. Although there are efforts to collect this information manually, they are limited by the size of the published literature on gene-drug relationships. Therefore, we investigated computational methods to extract and characterize pharmacogenetic relationships between genes and drugs from the literature. We first evaluated the effectiveness of the co-occurrence method in identifying related genes and drugs. We then used supervised machine learning algorithms to classify the relationships between genes and drugs from the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) into five categories that have been defined by active pharmacogenetic researchers as relevant to their work. The final co-occurrence algorithm was able to extract 78% of the related genes and drugs that were published in a review article from the literature. Our algorithm subsequently classified the relationships between genes and drugs from the PharmGKB into five categories with 74% accuracy. We have made the data available on a supplementary website at http:// bionlp.stanford.edu/genedrug/ Gene-drug relationships can be accurately extracted from text and classified into categories. Although the relationships that we have identified do not capture the details and fine distinctions often made in the literature, these methods will help scientists to track the ever-growing literature and create information resources to support future discoveries.
Introduction
A fundamental question in pharmacogenetics research concerns the discovery and characterization of relationships, particularly those between genes, between genes and drugs, and between drugs. Although such investigations have yielded copious findings, there is not yet an exhaustive database of such results. Any relationships that are uncovered are predominantly reported in the scientific literature in the form of unstructured free text and are thus inaccessible for computational analysis. Furthermore, the vast number and complexity of macromolecules and their relationships hamper manual efforts to identify them comprehensively. Consequently, high-throughput analysis of relationship data, to increase understanding and help guide the development of new hypotheses, is currently impractical. Therefore, methods are required that automatically extract relationships from text.
Methods exist for extracting protein-protein interactions [1] [2] [3] [4] [5] [6] [7] [8] , protein cellular localization [9] , metabolic enzymes [10] , gene-drug interactions [9, 11] , gene and gene products [12] , diseases associated with proteins or keywords [9, 13] , and other relationships [14] . The main approaches to extracting relationships employ co-occurrence, keyword matching, machine learning, and natural language processing. These methods have different accuracies, and more sophisticated ones can extract more detailed information about the relationships [6] .
A simple approach to finding related entities is based on the hypothesis that entities appearing in the same sentence or abstract are more likely to be related. Further refining this idea, entities that occur close to each other in an abstract, and entities that co-occur repeatedly across many abstracts, are more likely to be related [4, 13, 15, 16] . Jenssen et al. [4] used a co-occurrence algorithm to find related genes; they retrieved MEDLINE abstracts that contained at least two gene names from their dictionary of human genes. They counted the number of times each pair of genes cooccured and used human experts to evaluate whether the co-occurrence was biologically meaningful. This resulted in 60% precision and 51% recall. [Recall is the percentage of total gene-gene (or gene-drug) relationships that the algorithm correctly identified. Precision is the percentage of the predictions of the algorithm that were correct.] Gene-gene pairs occurring multiple times were more likely to be related. When considering only the relationships appearing in five or more articles, the precision increased to 72%. Nearly all unrecognized gene-gene interactions were due to failures in gene name identification.
There are also methods that require co-occurrences to occur in the same phrase [5] or sentence [11] . Intuitively, by restricting the length of text considered, the algorithms will detect fewer, but more accurate, relationships. The recall and precision for co-occurrences have been estimated to be, respectively, 100% and 57% for abstracts, 85% and 64% for sentences, and 62% and 74% for phrases [17] .
Although co-occurrence methods can successfully find relationships, they do not describe their characteristics. Co-occurrences between genes can indicate direct physical relationships, such as binding, or more abstract relationships, such as mutual involvement in a biological process [15] . Further processing is necessary to identify the type of relationship. To do so, algorithms examine the words or phrases that appear close to the co-occurrence, such as the verb [1] . One method is to develop patterns of key words or phrases known to identify particular types of relationships [2, 5, 16] . For example, one system used the pattern ,protein A. ,action. ,protein B. where ,action. consisted of a list of 14 possible words and their variants [1] . Relation extraction has also been framed as a machine learning problem. Documents with co-occurrences are represented as vectors, where each dimension in the vector corresponds to a word, and the value is the number of times the word occurs in the document. A classifier scores the likelihood that the document contains a relationship. This approach can determine subcellular localization of proteins [9] .
A fundamental limitation of the previously described methods is that they assume that the meanings of words are invariant regardless of context. More sophisticated language models can improve performance by including information about the structure of the sentence (its syntax) and its meaning (its semantics). Systems incorporating such models have been applied to identify various biological relationships [10, 18] . Although technologies to model knowledge and parse syntax are still under development, they often perform well enough for information extraction [12] . Thomas et al. [3] used part of speech information to find protein interactions with high precision. A number of groups have used shallow parsing to determine the subject and object of known verbs [7, 12, 19] . Others have used full parsing to ascertain the relationships among all components in a sentence [6, 8, 20] . Full parsers suffer from parsing ambiguities [8] , but can achieve up to 48% recall with 80% precision [6] . Nevertheless, such systems require specialized lexicons and must be adapted for use in specialized domains.
Gene-drug relationships in pharmacogenetics
To support research in pharmacogenetics, we are interested in extracting and characterizing the relationships between genes and drugs described in the literature. We define relationships broadly to include a range of associations of interest from physical binding to correlation with clinical outcomes. Characterizing such diverse pharmacogenetic relationships is difficult, and there has been little previous research into this problem.
One database working on cataloging gene and drug relationships is the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) [21] .
PharmGKB is currently compiling information about related genes and drugs from the research community [22] . Human annotators classify the evidence for genedrug relationships into five categories, depending on what is measured and shown to vary: (i) Clinical Outcome; (ii) Pharmacodynamics and Drug Response; (iii) Pharmacokinetics; (iv) Molecular and Cellular Functional Assays; and (v) Genotype ( Fig. 1 ; for detailed definitions, see http://www.pharmgkb.org/ resources/references/category.jsp). These categories overlap, but have been useful in annotating more than 343 published articles with respect to the type of relationship information that they contain. Because the aim of the categories is to enhance retrieval, their value is not that they are perfect but that they are good enough to stimulate hypothesis generation. Multiple categories can simultaneously apply to a specific genedrug pair. In particular, the consequences of Genotype variations are often revealed in the other categories. For example, a mutation in the TPMT gene can lead to blood toxicity of 6-thioguanine, indicating both Genotype and Pharmacodynamic relationships. 
Methods
In this study, we decomposed the extraction problem into two distinct tasks: (i) extracting related genes and drugs from literature and (ii) characterizing their relationships at the level of detail used by PharmGKB.
Extracting related genes and drugs
For the first task, we identified related genes and drugs based on their co-occurrences in the titles and abstracts of publications in MEDLINE. We evaluated the comprehensiveness of the algorithm in retrieving from the literature evidence of gene-drug relationships listed in a reference data set manually compiled from a review article [30] . This data set consists of 215 relationships between 62 genes and 127 drugs. The review article may not have included all known pharmacogenetic relationships, but the ones presented have high likelihood of being correct and thus can be considered a gold standard. We searched the abstracts and titles of MEDLINE citations for mentions of the genes and drugs from our compiled list. Each gene and drug word (or phrase) must have appeared in the text and be preceded and followed by either whitespace or punctuation. This ensured that spurious partial word matches were not found. We allowed variation in capitalization. If the word was an abbreviation or long form defined in the text, we also searched for the corresponding form in that citation. We recognized abbreviations using the algorithm described in [31] with a score cut-off of at least 0.03.
Next, for each gene-drug pair, we counted both the number of abstracts, as well as the number of sentences where both the gene and drug occurred. To split text into sentences, we used a sentence boundary detection heuristic that essentially looked for periods followed by whitespace. We did not count co-occurrences where the gene and drug names overlapped (e.g. if the vitamin D drug used the same words as the gene vitamin D receptor).
Characterizing relationships between genes and drugs
For the second task, we classified related genes and drugs into the categories defined by PharmGKB using a supervised machine learning algorithm called Maximum Entropy [32] . We evaluated our results on this task on human-curated articles of related genes and drugs from the PharmGKB. These relationships have been manually categorized into pharmacogenetic categories by the PharmGKB curators.
To classify references of co-occurring genes and drugs into the five types of relationship, we first searched MEDLINE for co-occurrences of each known genedrug pair in sentences, and then we trained machine learning classifiers to categorize their relationship based on the text in their sentences. For each gene-drug pair, we retrieved the MEDLINE citations (through the year 2001) that contained both the gene and the drug using the procedure described above. With the citations found, we created a data set of the sentences that contained a gene and drug. (The title was also considered a sentence.) From each sentence, we removed occurrences of all gene and drug names.
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Myocardial infarction survivors with the epsilon4 allele have a nearly two-fold increased risk of dying compared with other patients, and the excess mortality can be abolished by treatment with simvastatin 1 .
Clinical Outcome
Genetic variability in the context of a drug changes medical outcomes.
Example
CYP2D6 poor metabolizers exhibit 3-to 10-fold higher plasma concentrations after administration of metoprolol than extensive metabolizers 2 .
Pharmacodynamics and Drug Response
Genetic variation in drug targets can cause measurable differences in the response of an organism to a drug.
Example
The ratio of the total losartan area under the plasma concentration-time curve to the total E-3174 AUC was higher in the subject with the CYP2C9*3/*3 genotype 3 .
Pharmacokinetics
Genetic polymorphisms lead to variations in the levels or concentrations of drugs.
Example
Microinjection of heparin, a competitive IP3R blocker, induced neurite retraction 4 .
Molecular and Cellular Functional Assays
Data in this category demonstrate associations between genetic variation and laboratory assays.
Example
This study investigated the effect of the 102-T/C polymorphism in the 5-HT(2A) receptor gene on risperidone efficacy 5 .
Genotype
Variations in genotype is measured as sequence variation in individual genes. Relationships between drugs and genes. PharmGKB classifies gene-drug relationships into the five categories defined above [23] . For each category, we show a sample sentence found in the literature. These categories were defined by a research network of 10 active pharmacogenetics groups attempting to classify the types of pharmacogenetic data they collect [24] . 1 Gerdes et al. [25] ; 2 Wuttke et al. [26] ; 3 Yasar et al. [27] ; 4 Takei et al. [28] ; 5 Lane et al. [29] .
Example
We represented each document as a vector of words:
where w i was 1 if the word occurred in the document and 0 otherwise; n was the total number of unique words that occurred in the corpus. To eliminate uninformative words, we selected those words that showed the best ability to distinguish each of the PharmGKB relationships. We ranked all words using the chi-square test, which produced a P-value related to the strength of the association between each word and each PharmGKB relationship. For each relationship, we kept the 100 words that were most indicative of the category, and the 100 words that occurred much less than would be expected, resulting in a total set of 200 words. This resulted in a set of words that was small enough to be computationally tractable, and rich enough to capture information relevant to the classification decision. The most informative words for each relationship are shown in Table 1 .
Using vectors, each made only of words useful for distinguishing one of the five PharmGKB relationships, we trained maximum entropy classifiers to score the relationships described in a sentence. We trained one classifier for each type of relationship. To test our results, we randomly split our data into five equal size subsets. We trained the classifier on data consisting of four subsets, 80% of the data, and tested it on the remaining subset. By repeating this procedure five times, each time using a different subset for testing, we scored every sentence in the data set without having used that sentence in training. Finally, for each genedrug pair, we collected the scores for every relationship of every sentence in which the pair co-occurred. For
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. example, if the pair co-occurred in eight sentences, we collected 40 scores (eight sentences 3 five types of relationships). To obtain the score for a particular relationship for a gene-drug pair, we averaged the relationship score over all sentences with the cooccurrence (e.g. averaged the Clinical Outcome scores from the eight sentences). We considered an average score of at least 0.5, on a scale from 0 to 1, as evidence that the gene-drug pair has that type of relationship.
Results

Extracting related genes and drugs
We searched MEDLINE for abstracts that contained co-occurrences of genes and drugs from the reference data set of the published review article. Out of the 215 pairs in the data set, 167 (78%) appeared in at least one abstract and 113 (53%) in at least five (Fig. 2) . 32% of the gene-drug pairs from the data set did not appear in any sentence together. In nearly half the missing genedrug pairs (22 out of 48), the gene was a cytochrome P450 protein, whose nomenclature is diverse and difficult to recognize, as addressed in the Discussion. Although the analysis of abstracts missed some relationships, the co-occurrence-based algorithm also identified 1295 gene-drug pairs that did not appear in the reference data set. Out of 7874 possible gene-drug pairs (62 genes 3 127 drugs), 1462 (19%) occurred in at least one abstract. 489 (6%) occurred in five or more. We manually examined 100 of these pairs (the 50 occurring in the largest number of citations, and 50 random pairs occurring in only one citation), and found that 70 shared some relationship. Out of the remaining 30, for eight pairs, the text specifically documented that they had no relationship, and the rest were apparent errors from the co-occurrence algorithm. Table 2 shows 10 of these pairs, and the complete list is online at http://bionlp.stanford.edu/genedrug/
Characterizing the relationships between genes and drugs
We applied the classifiers (with cross validation) to the gene-drug relationships from the manually curated PharmGKB data set. We found 187 pairs of genes and drugs that co-occurred in the same sentences among the abstracts analysed. We scored each sentence with a co-occurrence for evidence that it describes one of the five PharmGKB relationships (Fig. 3) .
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Frequency of gene-drug co-occurrences. We searched MEDLINE for co-occurrences of related genes and drugs from a published review. For each gene-drug pair, we counted the number of times they were found in the same abstract and sentence and plotted the counts in this histogram. We could not find 68 of the 215 relationships when we required genes and drugs to appear in the same sentence. We missed 48 of them when we relaxed the requirement and allowed genes and drugs to appear in the same abstract. Of the gene-drug pairs observed, approximately half of them occurred between one and 10 times in the literature. The table describes the relationship between 10 genes and drugs found to co-occur in the literature, but were not identified in the reference data set from a published review article. The first five are the genes and drugs that appear in the greatest number of abstracts. The last five are randomly chosen genes and drugs that appear in one abstract only. The Abstracts column denotes the number of abstracts that contained both the gene and drug. Distribution of relationship scores. These histograms, one for each relationship, show the distribution of scores for sentences derived from genes and drugs in PharmGKB. The dark bars show the scores for sentences describing that relationship, and the hashed bars show the scores for other sentences. Thus, for example, the distributions for Pharmacokinetics and Pharmacodynamics and drugs responses are relatively well separated, while there is considerable overlap in distributions for Clinical outcome and Genotype. The scores on the horizontal axis are split into 20 evenly spaced bins from 0 to 1.
no decision based on whether each of the five PharmGKB types of relationships were suggested by the associated sentences. Thus, there were five yes/no predictions for each gene-drug pair. In 50 of the 187 gene-drug pairs, all five of their relationships were predicted correctly. Conversely, in five gene-drug pairs, only zero or one were correct (Fig. 4) . Those five pairs were CYP2D6-interferon alpha, CYP3A5-midazolam, CYP3A5-xenobiotics, CYP4B1-xenobiotics, and TPMT-sulfasalazine. Four of these involve cytochrome P450 proteins. A complete list of the genedrug pairs and the predictions of their relationships appear in the online supplement. The number of errors for each of the gene-drug pairs was related to the amount of data available (Fig. 5) . The maximum number of errors is five for each gene-drug pair (if each of the five categories is predicted correctly). Gene-drug pairs that co-occurred in only one sentence could be classified into the five types of relationships with an average of 1.89 errors. However, the error rate decreased to 1.45 in pairs that co-occurred in up to 10 sentences, and 1.36 in those co-occurring in up to 100.
Discussion
We applied the co-occurrence method of identifying related entities to finding relationships between genes and drugs; co-occurrence has not been applied to this type of relationship previously. We also developed a method to classify co-occurring genes and drugs into five categories of relationships of pharmacogenetic interest, and for which a human curated corpus is available.
A major source of errors in our algorithm arose in identifying gene and drug names, as is also seen in
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Categories predicted correctly. We applied a machine learning classifier to predict the categories of relationships exhibited by the gene-drug pairs in the PharmGKB. This chart shows the percentage of pairs (out of 187) in which different numbers of relationships were predicted correctly. In 27% of the pairs, the algorithm predicted all five types of relationships correctly. Common co-occurrences classified more accurately. This plot shows the frequency of errors obtained from different amounts of data. We classified each gene-drug pair into the five PharmGKB categories. The number of errors is the number of PharmGKB categories assigned incorrectly (i.e. between 0 and 5). Average Errors is the average number of errors for all gene-drug pairs found in at most Number of Sentences. The number of sentences is plotted on a log scale for clarity.
earlier studies of gene-gene relationships [4] . Nomenclature for the cytochrome P450 family, in particular, contains considerable variation that makes recognition difficult. These proteins could be written in many ways, including CYP1A1/2, CYP2D family, or more generally cytochrome p450 protein. In addition, use of cytochrome terminology has evolved as isoforms have been characterized. Older language is less specific and thus causes our algorithm more difficulties. In addition, a more sophisticated tokenizer that handled P450 nomenclature may have been able to recognize analogous references to the token from the gene name list. For example, the CYP3A5-midazolam co-occurrence appeared in one abstract as '. . . CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4 and 3A5, three (CYP2B6, 3A4 and 3A5) showed midazolam 19-hydroxylation activity . . .' [43] . Identifying these phrases, and resolving them as individual genes, would require more sophisticated strategies for tokenization and name resolution. Fortunately, usage is becoming more regular, and so we may have better performance when analysing current literature.
Similarly, there were many ways to refer to drugs. Drugs are commonly classified into categories, with references to classes of drugs rather than specific ones. For example, the drugs in our reference review included classes such as steroids, antipsychotics, and calcium channel blockers. Knowledge about classes of drugs would improve performance considerably. Resolving such discrepancies computationally would require a hierarchical classification of drugs, and rules for navigating this computationally [44] .
The co-occurrence criteria we used selected many gene-drug pairs that were not listed in our reference review. There are many reasons for the additional discovered associations. First, the review article concentrated mainly on the genes with polymorphisms that could affect drug response. The authors did not intend to catalog all known gene-drug relationships. Second, the review article contained only the relationships known to occur in humans. Because our MEDLINE search was not limited to a specific organism, some of the results described studies performed in model organisms. Many of the gene-drug pairs we identified shared a legitimate relationship, and thus represent, in a sense, a validation of our method. Our strategy of first searching for general types of relationships, and then refining them into specific categories ultimately results in a database that is both comprehensive (contains many types of relationships) and precise (distinguishes among relationships of interest). Nevertheless, there is a paucity of training data from PharmGKB for our statistical classifier. Some of the features used by the classifiers to recognize the five types of relationships in PharmGKB may be specific to the genes and drugs in this data set. We expect that, as the amount of data available grows, the features will become more general and recognize more diverse descriptions for each type of relationship. However, an issue that may further complicate the problem is that the vocabulary describing relationships may change with time, as new biology or new technologies are discovered. To address this, the data set should be stratified by date.
The PharmGKB curated data set we used was relatively small, including 442 submissions covering 325 gene-drug pairs. (Some of the submissions involved the same gene and drug.) Indeed, the difficulty in sustaining an effort in human curation was a major impetus for this automated approach. Over 70% of the submissions were contributed by four submitters (curators at PharmGKB). Homogeneity in the data submissions could have led to biases in the choice of articles and the assignment of PharmGKB categories. One strategy to increase the amount of training data is to examine co-occurrences in abstracts rather than sentences. If the whole abstract contains language that is distinct for a particular class, such as an abstract describing an outcome from a clinical trial, then an abstract-based strategy would be more likely to discover the associated words. In addition, this would recognize co-occurrences of gene and drug names separated by one or more sentences. However, previous studies on gene-gene relationships have suggested that reviewing more text would increase recall (the comprehensiveness in detecting all relationships) at the cost of precision (the accuracy of the relationships detected). Thus, it is not clear how abstract-based co-occurrence would affect the extraction of gene-drug relations.
Our results show clearly that the accuracy of predictions of the type of gene-drug relationships are dependent upon the number of sentences with the co-occurrence and the number of gene-drug pairs used in training. In addition, the amount of text required likely depends on the breadth of the vocabulary used to describe the relationship. For example, the Clinical Outcome and Genotype categories were most difficult to predict, and are associated with very diverse vocabularies. Pharmacokinetics texts use very standard vocabulary and thus are easier to recognize. For Genotype, genetic variations are often described in conjunction with other categories, and thus more data are needed to distinguish words describing genotypes from those describing the other categories. One possible solution is to use specific categories of relationships with more constrained vocabularies. This would require the development of more formally defined ontologies of gene-drug relationships, and it would be interesting to reformulate this problem once such a structure has matured.
Extracting relationships between genes and drugs from the literature is a complex problem. In particular, recognition of the basic entities, the genes and drugs, continues to be a major challenge. In this study, we used limited gene and drug lexicons to simplify the evaluation of our algorithm; we expect that using more complete lists of names would yield a more exhaustive set of related genes and drugs. However, our results show that gene-drug relationships can be extracted from text with good enrichment of true relationships relative to false relationships. Our results are available for browsing at http://bionlp.stanford.edu/genedrug/. The relationships can form the basis of more detailed pharmacogenetic experimental investigations.
